References
- Haldane JBS . The relative importance of principal and modifying genes in determining some human diseases. J. Genet.41(2–3), 149–157 (1941).
- Katz R . Biomarkers and surrogate markers: an FDA perspective. NeuroRx1(2), 189–195 (2004).
- Lessl M , BryansJS, RichardsD, AsadullahK. Crowd sourcing in drug discovery. Nat. Rev. Drug. Discov.10(4), 241–242 (2011).
- Landis SC , AmaraSG, AsadullahKet al. A call for transparent reporting to optimize the predictive value of preclinical research. Nature490(7419), 187–191 (2012).
Websites
- Guidance for industry: qualification process for drug development tools. www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM230597.pdf
- Biorepositories and Biospecimen Research. http://biospecimens.cancer.gov/default.asp
- PRO-ACT. https://nctu.partners.org/ProACT
- NeuroNEXT. www.neuronext.org